(EMAILWIRE.COM, September 20, 2018 ) Drivers:
1 High Prevalence of Infectious Diseases in Developing Countries
2 Increasing Incidence of Target Diseases
3 Rising Usage of Home-Based POC Devices
4 Growing Government Support
5 Technological Advancements and New Product Launches
6 Growing Number of Regulatory Approvals for Novel Immunoassay Techniques
7 Shortage of Skilled Laboratory Technicians
8 Rising Number of Clia-Waived POC Tests

Restraints:
1 Product Recalls: Hampering User Confidence
2 Pricing Pressure Owing to Reimbursement Cuts and Budget Constraints
3 Stringent and Time-Consuming Regulatory Policies are Significantly Increasing Gestation Period for Product Launches

PDF Brochure: https://www.marketsandmarkets.com/pdfdownload.asp?id=106829185

Opportunities:
1 Growth Opportunities in Emerging Markets
2 Healthcare Decentralization —Converting Lab Tests to POC Tests
3 Increasing Number of Conferences and Events
4 POC Tests With Multiplexing Capabilities

Challenges:
1 Lack of Alignment With Definitive Central Lab Methods
1.1 Disadvantages of POC Testing Over Central Lab Methods
2 Inadequate Knowledge About the Use of POC Devices in Professional Settings
3 Reluctance Towards Changing Existing Diagnostic Practices
4 High Cost of Devices

Market Key Players:

The major players of the Point-of-Care Diagnostics market are Abbott (US), Roche (Switzerland), Siemens (Germany), Danaher (US), Becton, Dickinson, and Company (US), Johnson & Johnson (US), Instrumentation Laboratory (US), PTS Diagnostics (US), Quidel (US), Chembio (US), Sekisui Diagnostics (US), Nova (US), EKF Diagnostics (UK), AccuBioTech (China), and Trinity Biotech (US).

Know More: https://www.marketsandmarkets.com/Market-Reports/point-of-care-diagnostic-market-106829185.html